Evidence map›Paper›PMID 23992368›Full record

ArticleBritish journal of pharmacology2013

The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

S Kheirallah, S Fruchon, L Ysebaert, A Blanc, F Capilla, A Marrot, T Alsaati, F X Frenois, K A Benhadji, J J Fournié and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

S KheirallahINSERM UMR1037-Centre de Recherche en Cancérologie de Toulouse, Toulouse, France; Université Toulouse III Paul-Sabatier, Toulouse, France; ERL 5294 CNRS, BP3028, Hôpital Purpan, Toulouse, France; Institut Carnot Lymphome-CALYM, Toulouse, France; Laboratoire d'Excellence Toulouse Cancer-TOUCAN, Toulouse, France.
S Fruchon
L Ysebaert
A Blanc
F Capilla
A Marrot
T Alsaati
F X Frenois
K A Benhadji
J J Fournié
G Laurent
C Bezombes
Hôpital Purpan · FRCentre National de la Recherche Scientifique · FRInserm · FRCentre de Physiopathologie de Toulouse-Purpan · FRLymphoma Study Association · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeFollicular lymphoma is the second most common non-Hodgkin's lymphoma and, despite the introduction of rituximab for its treatment, this disease is still considered incurable. Besides genetic alterations involving Bcl-2, Bcl-6 or c-Myc, follicular lymphoma cells often display altered B-cell receptor signalling pathways including overactive PKC and PI3K/Akt systems. EXPERIMENTAL APPROACH: The effect of enzastaurin, an inhibitor of PKC, was evaluated both in vitro on follicular lymphoma cell lines and in vivo on a xenograft murine model. Using pharmacological inhibitors and siRNA transfection, we determined the different signalling pathways after enzastaurin treatment. KEY

resultsEnzastaurin inhibited the serine-threonine kinase p90RSK which has downstream effects on GSK3β. Bad and p70S6K. These signalling proteins control follicular lymphoma cell survival and apoptosis; which accounted for the inhibition by enzastaurin of cell survival and its induction of apoptosis of follicular lymphoma cell lines in vitro. Importantly, these results were replicated in vivo where enzastaurin inhibited the growth of follicular lymphoma xenografts in mice. CONCLUSIONS AND IMPLICATIONS: The targeting of p90RSK by enzastaurin represents a new therapeutic option for the treatment of follicular lymphoma.

Indexed as

AnimalsAntineoplastic AgentsApoptosisbcl-Associated Death ProteinCell Line, TumorCell SurvivalDose-Response Relationship, DrugGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaLymphoma, FollicularMiceMice, SCIDMolecular Targeted TherapyPhosphorylationProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 70-kDaAntineoplastic AgentsBAD protein, humanbcl-Associated Death ProteinGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 70-kDaRibosomal Protein S6 Kinases, 90-kDaapoptosisBadenzastaurinfollicular lymphomaGSK3βp90RSK

Identifiers

PMID23992368
PMCPMC3838684
OpenAlexW1522068300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.